Skystar Bio Pharmaceutical Company Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013; Reiterates Revenue Guidance for the Year 2013
The company reiterated fiscal 2013 revenue guidance range of $40 million to $45 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 0 | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |